Oligonucleotide Synthesis Market to Reach Valuation of USD 24.1 Billion by 2030 – Decreasing Cost of Sequencing and Strategic Investments by Major Players Drives the Market

In terms of revenue, the Global Oligonucleotide Synthesis Market is expected to reach by 2030, growing at a CAGR (Compound Annual Growth Rate) of 16.1% from 2023 to 2030.

The Oligonucleotide Synthesis market is fuelled by the ability to create short, single-stranded DNA molecules with exact sequences. The ability to produce tailored DNA oligos with particular sequences made possible by this technique has increased their application in various life sciences fields, from fundamental research to therapeutics. Custom oligos are often used as probes to detect specific DNA sequences or as primers in Polymerase Chain Reaction (PCR) to amplify specific regions of DNA selectively. Adding improved bases to oligonucleotides has brought new improvements, particularly in gene therapy and other applications.

In medicine and life science research, oligonucleotide or gene synthesis is an essential tool supporting various applications. These applications include creating primers for DNA sequencing and amplification, developing probes for detecting complementary DNA or RNA, synthesizing artificial genes, producing antisense oligonucleotides for clinical development, and providing tools for introducing genetic mutations.

The lowering cost of sequencing has caused a better demand for custom-designed nucleotides for genetic testing, research, forensics, and drug improvement. The COVID-19 pandemic has also fuelled this increased demand. Healthcare providers and pharmaceutical companies are exploring the potential use of oligonucleotides to develop efficient treatments against COVID-19. For example, the Innovative Genomics Institute is working on developing new therapies for COVID-19 patients with respiratory symptoms using antisense oligonucleotide therapeutics.

Key Highlights from the Report

• Based on the Product segmentation, the Synthesized Oligonucleotides segment is expected to flourish in the market during the forecast period owing to advancements in molecular biology techniques, increasing demand for personalized medicine, and the rising use of oligonucleotide-based therapies.
• Furthermore, based on the segmentation of Application, the Therapeutic Application segment is anticipated to witness the most considerable growth of the market over projected time owing to the increased understanding of the role of nucleic acids in diseases and the potential for personalized medicine.
• Moreover, based on the End User segmentation, the Pharmaceutical & Biotechnology Companies’ segment is predicted to witness the most significant growth of the market over projected time owing to the development of oligonucleotide-based drugs and their use in target screening and identification.
• Finally, based on the Region, North America holds the significant market share within the Oligonucleotide Synthesis market in 2022 owing to the presence of a large number of companies as well as research institutes creating high demand for oligonucleotides.

Market Dynamics

The industry's decision to make strategic investments demonstrates their acknowledgment of the market's potential for growth and the growing significance of therapeutics utilizing oligonucleotides. For instance, Agilent Technologies is making an investment $725 million to amplify its production potential for healing nucleic acids, mainly oligonucleotides, to drive the growth of the Oligonucleotide Synthesis market. This investment is in response to the market's rapid growth and current value of $1 billion annually. Agilent is committed to supporting existing and new biopharma customers, particularly in small interfering RNAs (siRNA), antisense molecules, and CRISPR guide RNA programs. This announcement reflects a broader trend in the industry, with other companies also making significant investments to meet the increasing demand for oligonucleotide-based therapeutics.

North America led the Oligonucleotide Synthesis market in 2022. The Oligonucleotide Synthesis market is experiencing large growth due to the growing variety of instructional and industrial laboratories and the growing number of biotech and pharmaceutical businesses in this region. For instance, ABC Biotech, a famous biotech organisation, plans to establish a modern Oligonucleotide Synthesis facility to enhance its research and development competencies. ABC Biotech's collaboration with academic institutions and pharmaceutical companies also contributes to the growing demand for customized oligonucleotides in the region. These collaborative efforts aim to develop new diagnostic tests and therapies requiring specific molecular probes and primers. The increasing presence of laboratory and strategic industry initiatives in this region as a leading force in the booming Oligonucleotide Synthesis market.

The Global Oligonucleotide Synthesis Market is Segmented as follows

• Product
  • Synthesized Oligonucleotides
  • Oligonucleotide-based Drugs
  • Reagents
  • Equipment
• Application
  • Therapeutic Applications
  • Diagnostic Applications
  • Research Applications
• End User
  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • CROs and CMOs
  • Academic Research Institutes
• Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

List of the Key Players of the Global Oligonucleotide Synthesis Market is

Agilent Technologies Inc. (U.S.), Atdbio Ltd. (UK), LGC Limited (UK), Bio-Synthesis Inc. (U.S.), Eurofins Genomics (Luxembourg), Kaneka Eurogentec S.A. (Belgium), General Electric (U.S.), Genscript (U.S.), Ajinomoto Co. Inc. (Japan), Danaher Corp. (U.S.), Merck Kgaa (Germany) 

The Global Oligonucleotide Synthesis Market Scope can be Tabulated as below